Here’s to why Bellicum Inc. (BLCM) stock rises during current market trading session?

0
402
Best Drone Stocks
Best Drone Stocks

Bellicum Inc. (NASDAQ: BLCM) stock gained by 28.38% in the current market trading session. Bellicum is a pharmaceutical business in the early stages of development that aims to cure diseases via controlled cell therapies.

>> 7 Top Picks for the Post-Pandemic Economy << 

BLCM stock’ Current Development

The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals declared today a major option and license agreement attempting to cover certain intellectual property and technology rights linked to Bellicum’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, as well as the use of rimiducid which is an agent used to stimulate the safety switch. MD Anderson will have the possibility to include CaspaCIDe into certain cellular therapy initiatives under the terms of this agreement.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Read More

Bellicum’s CaspaCIDe safety switch could make it easier to use cell therapies in situations where cytokine release syndrome and neurotoxicity have been reported, in the search for new targets with on-target/off-tumor safety concerns, and in combination with next-generation greater potency cell therapy constructs.

Rick Fair, President, and CEO of BLCM stated,

They’re excited to broaden their CaspaCIDe partnership with MD Anderson to provide a larger range of cancer-related programmes. The switch technology, they believe, could improve the benefit/risk balance of cell treatments. They want to keep looking for ways to increase its application through external cooperation with other thought leaders in the sector.

Furthermore,

Each option is normally expected to be exercised upon out-licensing of an MD Anderson programme that includes iC9. Bellicum will be paid upfront and will be allowed to be part of the third-party compensation given to MD Anderson. Bellicum will also get a royalty on global sales of the product in the single digits. The financial dealings are kept under wraps for the time being. Bellicum and MD Anderson have agreed to develop the first two programmes concurrently with the agreement’s execution. This deal builds on a prior one that covered CaspaCIDe’s usage in a specific MD Anderson cell therapy programme.

LEAVE A REPLY

Please enter your comment!
Please enter your name here